Andersons pediatric cardiology 353
Bạn đang xem bản rút gọn của tài liệu. Xem và tải ngay bản đầy đủ của tài liệu tại đây (60.72 KB, 3 trang )
285.AlsoufiB,McCrackenC,EhrlichA,etal.Single
ventriclepalliationinlowweightpatientsis
associatedwithworseearlyandmidterm
outcomes.AnnThoracSurg.2015;99(2):668–
676.
286.AndersonAW,SmithPB,CoreyKM,etal.
Clinicaloutcomesinverylowbirthweight
infantswithmajorcongenitalheartdefects.
EarlyHumDev.2014;90(12):791–795.
287.AxelrodDM,ChockVY,ReddyVM.
Managementofthepreterminfantwith
congenitalheartdisease.ClinPerinatol.
2016;43(1):157–171.
288.PolitoA,PigaS,CogoPE,etal.Increased
morbidityandmortalityinverypreterm/VLBW
infantswithcongenitalheartdisease.Intensive
CareMed.2013;39(6):1104–1112.
289.CnotaJF,GuptaR,MichelfelderEC,Ittenbach
RF.Congenitalheartdiseaseinfantdeathrates
decreaseasgestationalageadvancesfrom34to
40weeks.JPediatr.2011;159(5):761–765.
290.WernovskyG,RubensteinSD,SprayTL.
Cardiacsurgeryinthelow-birthweightneonate.
Newapproaches.ClinPerinatol.
2001;28(1):249–264.
291.WolterA,HoltmannH,KaweckiA,etal.
Perinataloutcomesofcongenitalheartdisease
afteremergentneonatalcardiacprocedures.The
journalofmaternal-fetal&neonatalmedicine:
theofficialjournaloftheEuropeanAssociation
ofPerinatalMedicine,theFederationofAsia
andOceaniaPerinatalSocieties,the
InternationalSocietyofPerinatalObstet.
2017;1–8.
292.HuangFK,LinCC,HuangTC,etal.Reappraisal
oftheprostaglandinE1doseforearlynewborns
withpatentductusarteriosus-dependent
pulmonarycirculation.PediatrNeonatol.
2013;54(2):102–106.
293.KidaT,SawadaK,KobayashiK,etal.Diverse
effectsofprostaglandinE(2)onvascular
contractility.HeartVessels.2014;29(3):390–395.
294.TodML,CassinS.Effectsof6-ketoprostaglandinE1onperinatalpulmonary
vascularresistance.ProcSocExpBiolMed.
1981;166(1):148–152.
295.AlhussinW,VerklanMT.Complicationsof
Long-termprostaglandinE1useinnewborns
withDuctal-dependentcriticalcongenitalheart
disease.JPerinatNeonatalNurs.
2016;30(1):73–79.
296.SiljehavV,HofstetterAM,LeifsdottirK,
HerleniusE.ProstaglandinE2mediates
cardiorespiratorydisturbancesduringinfection
inneonates.JPediatr.2015;167(6):1207–1213
[e3].
297.TomsR,JacksonKW,DabalRJ,ReebalsCH,
AltenJA.Preoperativetrophicfeedsinneonates
withhypoplasticleftheartsyndrome.Congenit
HeartDis.2015;10(1):36–42.
298.KooiEMW,VerhagenEA,EltingJWJ,etal.
Measuringcerebrovascularautoregulationin
preterminfantsusingnear-infrared
spectroscopy:anoverviewoftheliterature.
ExpertRevNeurother.2017;17(8):801–818.
299.Hyttel-SorensenS,PellicerA,AlderliestenT,et
al.Cerebralnearinfraredspectroscopyoximetry
inextremelypreterminfants:phaseII
randomisedclinicaltrial.BMJ.2015;350:g7635.
300.SchatTE,vanderLaanME,SchurinkM,etal.
Assessingcerebrovascularautoregulationin
infantswithnecrotizingenterocolitisusingnearinfraredspectroscopy.PediatrRes.2016;79(1–
1):76–80.
301.vanderLaanME,SchatTE,OlthuisAJ,etal.
TheassociationbetweenmultisiteNear-infrared
spectroscopyandroutinehemodynamic
measurementsinrelationtoShort-termoutcome
inpretermswithclinicalsepsis.Neonatology.
2015;108(4):297–304.
302.SchwartzMC,RomeJJ,GillespieMJ,etal.
